| Predicting PSA Failure Following Salvage Radiotherapy for a Rising PSA Post-Prostatectomy: From the CaPSUREtrade Mark Database - Abstract |
|
|
|
|
|
| Monday, 12 May 2008 | ||
|
Huntsman Cancer Hospital, Salt Lake City, UT 84112, USA. The role of radiotherapy (RT) for rising PSA after radical prostatectomy (RP) is debatable. We analyzed a large database of men to evaluate for predictors of prostate-specific antigen (PSA) failure after salvage RT. Data from the Cancer of the Prostate Strategic Urologic Research Endeavor database (CaPSUREtrade mark) identified 4,563 men with RP between 1989 and 2004; 194 underwent salvage RT >/=6 months after RP. PSA failure following RT was defined as a PSA >0.2 ng/ml. The association between clinical and pathologic characteristics and PSA failure was examined using a chi-square metric. A multivariable analysis of predictors for time to PSA failure was performed using a Cox proportional hazard regression model. After a median follow-up of 66 months, 121 (62%) men experienced PSA failure at a median 20 months. Significant associations for PSA failure were found for the clinical T category (P < .01), race/ethnicity (P = 0.04), pT3 disease (P < 0.01), seminal vesicle invasion (P < 0.01), and pre-RT PSA level (P < 0.01). The pre-RT PSA level (P = 0.07) was the only factor to approach significance as an independent predictor of PSA failure on multivariable analysis. Pre-RT PSA doubling time was calculated for 131 men but did not predict for PSA failure on univariate (P = 0.38) or multivariate analyses (P = 0.13) for 12 months. Salvage RT provided the greatest benefit in PSA control in men with the lowest pre-RT PSA levels. Post-RP PSA doubling time >12 months trended toward predicting for PSA failure but was not significant likely owing to limited sample size. Together, these findings would suggest that salvage RT is optimal at low pre-RT PSA and long doubling times with favorable pathologic features. Written by Reference PubMed Abstract UroToday.com Prostate Cancer Section
Please log-in or register in order to submit comments. Powered by AkoComment! |
||
| < Prev | Next > |
|---|
|
UroToday, 1802 Fifth Street, Berkeley CA 94710 510.540.0930 (fax), info@urotoday.com ISSN 1939-4810
Privacy Policy | © 2008 UroToday ® All Rights Reserved |











